Results 11 to 20 of about 698,293 (229)
Competitive Enzyme Immunoassay for Apolipoprotein A-II [PDF]
cclm, 1983 A competitive enzyme immunoassay for apolipoprotein A-II was developed. Microtitre plates were used as a solid phase and coated with anti-apolipoprotein A-II antibodies. Purified apolipoprotein A-II, labelled with horseradish peroxidase was used as competing ligand.
Dufaux, B., Ilsemann, K., Assmann, G.
openaire +3 more sources
APO A2 -265T/C Polymorphism Is Associated with Increased Inflammatory Responses in Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2016 BackgroundApolipoprotein A2 (APO A2) is the second most abundant structural apolipoprotein in high density lipoprotein. Several studies have examined the possible effect of APO A2 on atherosclerosis incidence.
Fariba Koohdani +7 more
doaj +1 more source
Journal of Lipid Research, 2003 Senescence-accelerated mouse-prone (SAMP1; SAMP1@Umz) is an animal model of senile amyloidosis with apolipoprotein A-II (apoA-II) amyloid fibril (AApoAII) deposits.
Makiko Umezawa +8 more
doaj +1 more source
The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B [PDF]
Diabetes & Metabolism Journal, 2012 BackgroundApolipoprotein A-II (apoA-II) is the second-most abundant apolipoprotein in human high-density lipoprotein and its role in cardio metabolic risk is not entirely clear.
Dong Won Yi +4 more
doaj +1 more source
Journal of Lipid Research, 2006 Plasma phospholipid transfer protein (PLTP) is a multifaceted protein with diverse biological functions. It has been shown to exist in both active and inactive forms.
Marian C. Cheung, John J. Albers
doaj +1 more source
Circulation Research, 2003 Familial combined hyperlipidemia (FCH) was originally identified as a new phenotype in studies of survivors of myocardial infarctions and their relatives.1–3 Patients with FCH were found to present with any of three patterns of lipoprotein distribution: elevated plasma levels of very low-density lipoprotein (VLDL) or low-density lipoprotein (LDL) or ...
Bradley E, Aouizerat, John P, Kane
openaire +2 more sources
Journal of Lipid Research, 2006 Endothelial lipase (EL) plays an important physiological role in modulating HDL metabolism. Data suggest that plasma contains an inhibitor of EL, and previous studies have suggested that apolipoprotein A-II (apoA-II) inhibits the activity of several ...
Uli C. Broedl +4 more
doaj +1 more source
Journal of Lipid Research, 2017 HDLs are a family of heterogeneous particles that vary in size, composition, and function. The structure of most HDLs is maintained by two scaffold proteins, apoA-I and apoA-II, but up to 95 other “accessory” proteins have been found associated with the ...
J. Melchior +11 more
semanticscholar +1 more source
Effect of urotensin II on apolipoprotein B 100 and apolipoprotein A-I expression in HepG2 cell line
Advanced Biomedical Research, 2014 Background: Increased apolipoprotein B100 (apo B) and decreased apolipoprotein A-I (apo A-I) production are important risk factors in atherosclerosis.
Abbas Mohammadi +2 more
doaj +1 more source
PLoS ONE, 2016 Background Apolipoprotein A-II (ApoA-II) is down regulated in the sera of pancreatic ductal adenocarcinoma (PDAC) patients, which may be due to increase utilization of high density lipoprotein (HDL) lipid by pancreatic cancer tissue.
S. Julovi +9 more
semanticscholar +1 more source